Suggested remit: To appraise the clinical and cost effectiveness of canagliflozin within its marketing authorisation for treating chronic kidney disease in people with type 2 diabetes. The Topic Selection Oversight Panel (TSOP) have determined that cangliflozin would be best assessed and included in the chronic kidney disease and Type 2 diabetes in adults: management update. Therefore the appraisal has been suspended from the Technology Appraisal work programme.
Suspended
 
Status Suspended
Process STA 2018
ID number 1653

Project Team

Project lead Danielle Lees

Email enquiries

Consultees

Companies sponsors Napp Pharmaceuticals (canagliflozin)
Others Department of Health and Social Care
  NHS England
  NHS Newbury and District CCG
  NHS Sheffield CCG
  Welsh Government
Patient carer groups BEMDA: Black and Ethnic Minority Diabetes Association
  Black Health Agency
  Diabetes Research and Wellness Foundation
  Diabetes UK
  Heart UK
  InDependent Diabetes Trust
  INPUT
  Kidney Care UK
  Kidney Research UK
  Muslim Council of Britain
  National Kidney Federation
  Network of Sikh Organisations
  Polycystic Kidney Disease Charity
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Stroke Association
Professional groups 4front
  Association for the Study of Obesity
  Association of British Clinical Diabetologists
  Association of Renal Technologists
  British and Irish Hypertension Society
  British Association for Nursing in Cardiovascular Care
  British Association of Endocrine and Thyroid Nurses
  British Geriatrics Society
  British Heart Foundation
  British Renal Society
  National Metabolic Biochemistry Network
  Primary Care Diabetes Society
  Renal Association
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for DGH Nephrologists
  Society for Endocrinology
  TREND UK
  UK Clinical Pharmacy Association
  UK Renal Pharmacy Group

Commentators

General commentators All Wales Therapeutic and Toxicology Centre
  Allied Health Professionals Federation
  Association of Renal Industries
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Diabetes UK Cymru
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Endocrine and Diabetes Society
  Welsh Health Specialised Services Committee
  Welsh Kidney Patients Association
Relevant research groups Cochrane Kidney and Transplant Group
  Cochrane Metabolic & Endocrine Disorders Group
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research
  The Society for Research in Rehabilitation
  Wellcome Trust

Timeline

Key events during the development of the guidance:

Date Update
22 December 2020 The Topic Selection Oversight Panel (TSOP) have determined that cangliflozin would be best assessed and included in the chronic kidney disease and Type 2 diabetes in adults: management update. Therefore the appraisal has been suspended from the Technology Appraisal work programme.
22 December 2020 Suspended. Suspended
07 May 2020 Invitation to participate
07 May 2020 Schedule affected by COVID-19. Invitation to participate issued but schedule affected by COVID-19
06 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
18 November 2019 - 16 December 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance